Table 1.
Baseline clinical information and antimicrobial susceptibilities to selected antibiotics of IMP-positive P. aeruginosa isolates
| P. aeruginosa isolate | Geographical regiona | Age (yrs) | Genderb | Anatomical site of collectionc | Hospital unitd | Test agente MIC (μg/ml) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FEP | ATM | TZP | IPM | MEM | DORf | CST | ||||||
| M1PA9-12 | San Juan metropolitan | 73 | M | RT | ICU | >16 | >16 | 34/4 | >8 | >8 | >2 | 2 |
| M1PA9-15 | San Juan metropolitan | 66 | M | UT | Gen Ward | >16 | 8 | 16/4 | >8 | >8 | >2 | 2 |
| S1PA9-25 | South | 0.08 | M | RT | ICU | >16 | <2 | 8/4 | >8 | <1 | 2 | 1 |
| C1PA9-07 | Central | 56 | M | UT | ICU | >16 | >16 | <8/4 | >8 | <1 | 2 | 4 |
| E1PA9-8 | East | 92 | M | RT | ICU | >16 | >16 | 32/4 | >8 | >8 | >2 | 1 |
| MC1PA9-13 | PRMC | 27 | F | RT | Gen Ward | >16 | 4 | 16/4 | >8 | >8 | >2 | 4 |
| MC1PA9-25 | PRMC | 63 | M | UT | Gen Ward | >16 | >16 | >64/4 | >8 | >8 | >2 | 2 |
| MC1PA9-33 | PRMC | 58 | M | Blood | Gen Ward | >16 | 16 | >64/4 | >8 | >8 | >2 | 2 |
| MC1PA9-34 | PRMC | 60 | F | Blood | ICU | >16 | 4 | 8/4 | >8 | >8 | >2 | 2 |
| MC1PA9-37 | PRMC | 65 | M | UT | Gen Ward | >16 | 16 | >64/4 | >8 | >8 | >2 | 2 |
| MC1PA9-38 | PRMC | 41 | M | Blood | Gen Ward | >16 | 16 | 64/4 | >8 | >8 | >2 | 2 |
| MC7PA9-5 | PRMC | 89 | M | UT | Gen Ward | >16 | 8 | 64/4 | >8 | >8 | >2 | 2 |
a
PRMC, Puerto Rico Medical Center.
b
M, male; F, female.
c
RT, respiratory tract; UT, urinary tract.
d
ICU, intensive care unit; Gen Ward, general ward.
e
Test agents and their Clinical and Laboratory Standards Institute (CLSI) susceptibility breakpoints (in μg/ml): FEP, cefepime (≤8); ATM, aztreonam (≤8); TZP, piperacillin-tazobactam (≥64/4); IPM, imipenem (≤4); MEM, meropenem (≤4); DOR, doripenem (≤2); CST, colistin (≤2).
f
The doripenem breakpoint value was obtained from the Doribax package insert.